Global cancer control : responding to the growing burden, rising costs and inequalities in access - Prager, Gerald W. (Medical University of Vienna) ; Braga, Sofia (Instituto CUF Oncologia) ; Bystricky, Branislav (Faculty Hospital Trencin) ; Qvortrup, Camilla (Odense University Hospital (Dinamarca)) ; Criscitiello, Carmen (Istituto Europeo di Oncologia) ; Esin, Ece (Ankara Oncology Education and Research Hospital) ; Sonke, Gabe S. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Frenel, Jean-Sebastian (Institut de Cancerologie de l'Ouest Saint-Herblain) ; Karamouzis, Michalis (National and Kapodistrian University of Athens) ; Strijbos, Michiel (AZ KLINA Hospitals) ; Yazici, Ozan (Ankara Numune Education and Research Hospital) ; Bossi, Paolo (Fondazione IRCCS Istituto Nazionale Tumori Milano) ; Banerjee, Susana (Royal Marsden Hospital (Regne Unit)) ; Troiani, Teresa (Università degli Studi della Campania Luigi Vanvitelli) ; Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ; Ciardiello, Fortunato (Università degli Studi della Campania Luigi Vanvitelli) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Zielinski, Christoph C. (Universitätskliniken der MedUni Wien) ; Casali, Paolo Giovanni (Istituto Nazionale Tumori) ; Cardoso, Fatima (Champalimaud Clinical Center) ; Douillard, Jean-Yves (European Society for Medical Oncology) ; Jezdic, Svetlana (European Society for Medical Oncology) ; McGregor, Keith (European Society for Medical Oncology) ; Bricalli, Gracemarie (European Society for Medical Oncology) ; Vyas, Malvika (European Society for Medical Oncology) ; Ilbawi, André (Disability, Violence and Injury Prevention (NVI), World Health Organization)
 
Comentaris (0) | Ressenyes (0)
Sigueu el primer a escriure una ressenya d'aquest document.

Afegiu la vostra ressenya

Valoreu aquest article:
Doneu un títol a la vostra ressenya:
Escriviu la vostra ressenya:
Vigileu: encara no heu definit el vostre àlies.
N/D s'usarà temporalment com a autor d'aquest comentari.